NASDAQ:CDXS Codexis (CDXS) Stock Price, News & Analysis $2.53 -0.05 (-1.94%) As of 05/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Codexis Stock (NASDAQ:CDXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Codexis alerts:Sign Up Key Stats Today's Range$2.46▼$2.6050-Day Range$1.27▼$2.8552-Week Range$0.96▼$3.87Volume694,915 shsAverage Volume1.21 million shsMarket Capitalization$229.98 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Codexis, Inc., headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact. Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production. The company operates advanced research and development laboratories alongside cGMP manufacturing facilities, allowing for seamless scale-up of enzyme processes. Its multidisciplinary team of molecular biologists, biochemists and process engineers collaborates closely with clients to integrate tailored enzyme solutions into existing production workflows. Codexis’s biocatalysts have been applied to the synthesis of active pharmaceutical ingredients, delivering streamlined routes and cost reductions in drug manufacturing. Beyond pharmaceuticals, the company addresses challenges in the food and beverage sector—such as flavor enhancement and ingredient processing—and in the fine chemicals and agricultural markets. Codexis’s commitment to sustainable biocatalysis supports industry efforts toward greener chemistry and resource conservation. Serving a global customer base, Codexis engages in partnerships and licensing arrangements with leading industrial and pharmaceutical organizations. Its commercial model typically combines research funding, milestone payments and royalty streams, positioning the company for diversified revenue growth across multiple projects. With an emphasis on innovation and environmental stewardship, Codexis continues to drive advancements in the burgeoning field of enzyme-based manufacturing. AI Generated. May Contain Errors. Read More Codexis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCDXS MarketRank™: Codexis scored higher than 50% of companies evaluated by MarketBeat, and ranked 516th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCodexis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCodexis has a consensus price target of $5.00, representing about 97.6% upside from its current price of $2.53.Amount of Analyst CoverageCodexis has only been the subject of 2 research reports in the past 90 days.Read more about Codexis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.39) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -6.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -6.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 5.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.33% of the float of Codexis has been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 3.66, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Codexis has recently decreased by 25.51%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Codexis this week, compared to 2 articles on an average week.Search Interest12 people have searched for CDXS on MarketBeat in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,624.00 in company stock.Percentage Held by Insiders3.50% of the stock of Codexis is held by insiders.Percentage Held by Institutions78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Codexis' insider trading history. Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CDXS Stock News HeadlinesCodexis (NASDAQ:CDXS) Stock Crosses Above Two Hundred Day Moving Average - Here's WhyMay 21 at 1:58 AM | americanbankingnews.comEarnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58May 11, 2026 | finance.yahoo.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 22 at 1:00 AM | Porter & Company (Ad)Codexis Earnings Call Balances Breakthroughs and RisksMay 8, 2026 | tipranks.comCodexis (CDXS) Q1 2026 Earnings TranscriptMay 8, 2026 | fool.comCodexis, Inc. (CDXS) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comCodexis: Q1 Earnings SnapshotMay 7, 2026 | sfgate.comCodexis Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comSee More Headlines CDXS Stock Analysis - Frequently Asked Questions How have CDXS shares performed this year? Codexis' stock was trading at $1.63 at the beginning of the year. Since then, CDXS shares have increased by 55.2% and is now trading at $2.53. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) announced its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. The biotechnology company earned $15.25 million during the quarter, compared to the consensus estimate of $14.53 million. Codexis had a negative trailing twelve-month return on equity of 68.09% and a negative net margin of 40.97%. Read the conference call transcript. When did Codexis IPO? Codexis (CDXS) raised $0 in an IPO on Thursday, April 22nd 2010. The company issued 0 shares at $0.00-$13.00 per share. Who are Codexis' major shareholders? Top institutional shareholders of Codexis include Private Advisor Group LLC (0.93%), Assenagon Asset Management S.A. (0.83%), Dimensional Fund Advisors LP (0.31%) and Lazard Asset Management LLC (0.31%). Insiders that own company stock include Opaleye Management Inc, Alison Moore, Byron L Dorgan, Stefan Lutz, Sriram Ryali, Kevin Norrett, Margaret Nell Fitzgerald and Georgia Erbez. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/07/2026Today5/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CDXS's financial health is in the Green zone, according to TradeSmith. CDXS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:CDXS CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees250Year Founded2002Price Target and Rating Average Price Target for Codexis$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+97.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.97 million Net Margins-40.97% Pretax Margin-40.87% Return on Equity-68.09% Return on Assets-23.72% Debt Debt-to-Equity Ratio0.94 Current Ratio5.36 Quick Ratio5.23 Sales & Book Value Annual Sales$70.39 million Price / Sales3.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book5.27Miscellaneous Outstanding Shares90,900,000Free Float87,716,000Market Cap$229.98 million OptionableOptionable Beta2.52 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:CDXS) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
